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Abstract
Background/objective: Mauriac  syndrome  (MS)  is  a  rare  complication  of  type  1  diabetes  mellitus
(DM1). It  is  related  to  low  insulin  concentrations  and  is  less  common  since  longer-acting  insulins
became  available.  It  is  characterized  by  hepatomegaly,  growth  and  puberty  delay,  and  the
presence of  elevated  transaminases  and  serum  lipids.  The  aim  of  this  study  was  to  describe  the
patients from  a  pediatric  diabetic  population  that  fulﬁll  the  criteria  of  MS.
Materials  and  methods:  A  retrospective  analysis  of  the  pediatric  diabetic  population  with  diag-
nostic criteria  of  MS  currently  followed  at  Hospital  de  Braga,  was  performed.
Results:  From  a  population  of  91  patients  with  DM1  18  years,  6  patients  with  the  criteria  for  MS
were identiﬁed:  5  girls,  and  1  boy.  The  age  at  presentation  was  13--17  years,  with  a  minimum
interval between  DM1  diagnosis  and  MS  criteria  of  4  years.  All  the  patients  were  prescribed
intensive  insulin  therapy  (median  daily  insulin  dose:  0.88  U/kg).  All  had  a  previous  history  of
poor glycemic  control  before  the  diagnosis  of  MS  with  glycated  hemoglobin  (HbA1c)  between
8.8 and  12.9%.  Increase  of  hepatic  enzymes  was  present  in  all  the  patients;  4  of  them  had
associated  hepatomegaly.  All  the  girls  presented  puberty  delay  and  cushingoid  features.  None
of the  patients  presented  short  stature  and  5  of  them  presented  mixed  dyslipidemia.
Conclusions:  Although  MS  is  an  ancient  entity  described  in  DM1,  it  still  exists,  particularly  in
adolescent  females.  Being  aware  of  MS  is  of  extreme  importance  since  most  of  the  clinical
features are  reversible  with  better  glycemic  control.
© 2012  SEEN.  Published  by  Elsevier  España,  S.L.  All  rights  reserved.
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ResumenPlease  cite  this  article  in  press  as:  Dias  J,  et  al.  Mauriac  syndrome  still  exists.  Endocrinol  Nutr.  2013.
http://dx.doi.org/10.1016/j.endonu.2012.12.005
Adolescencia Introducción/objetivo:  El  síndrome  de  Mauriac  (SM)  es  una  complicación  rara  de  la  diabetes
mellitus  de  tipo  1  (DM1),  relacionada  con  bajas  concentraciones  de  insulina,  y  es  menos  común
desde que  están  disponibles  insulinas  de  larga  duración  de  acción.  Se  caracteriza  por  la  hep-
atomegalia,  el  retraso  del  crecimiento  y  de  la  pubertad  y  la  elevación  de  las  transaminasas  y  de
los lípidos  séricos.  El  objetivo  de  este  estudio  fue  la  descripción  de  los  pacientes  con  criterios
de SM  en  una  población  pediátrica  con  DM1.
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Material  y  métodos: Análisis  retrospectivo  de  una  población  pediátrica  diabética  atendida  en
el Hospital  de  Braga  con  criterios  diagnósticos  de  SM.
Resultados:  De  una  población  de  91  pacientes  con  DM1  menores  de  18  an˜os  fueron  identiﬁcados
6 pacientes  con  criterios  de  SM:  5  mujeres  y  un  varón.  La  edad  de  presentación  fue  de  13  a  17
an˜os con  un  intervalo  mínimo  entre  el  diagnóstico  de  DM1  y  SM  de  4  an˜os.  Todos  los  pacientes
tenían prescrita  una  terapia  insulínica  intensiva  (dosis  media  diaria:  0,88  U/kg).  Todos  tenían
una historia  previa  de  mal  control  glucémico  antes  del  diagnóstico  de  SM  con  hemoglobina
glucosilada  (HbA1c)  entre  8,8  y  12,9%.  Las  enzimas  hepáticas  estaban  aumentadas  en  todos  los
pacientes y  4  presentaban  una  hepatomegalia  asociada.  Todas  las  nin˜as  mostraban  retraso  de
la pubertad  y  un  aspecto  cushingoide.  Ningún  paciente  tenia  talla  baja  y  5  tenían  dislipidemia
mixta.
Conclusiones:  Aunque  el  SM  es  una  entidad  poco  descrita  actualmente,  aún  existe,  especial-
mente en  adolescentes  femeninas.  Identiﬁcar  el  SM  es  muy  importante  ya  que  la  mayoría  de
las alteraciones  clínicas  son  reversibles  con  mejor  control  glucémico.
© 2012  SEEN.  Publicado  por  Elsevier  España,  S.L.  Todos  los  derechos  reservados.
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auriac  syndrome  (MS)  is  a  rare  complication  of  type  1
iabetes  mellitus  (DM1),  characterized  by  hepatomegaly
hepatic  glycogenosis),  puberty  and  growth  delay,  dys-
ipidemia,  transaminase  elevation  and  reduction  of  IGF1
insulin-like  growth  factor  1).1 Cushingoid  features  may  also
e  present.2
There  may  be  different  forms  and  etiologies  involved  in
auriac  syndrome.  However,  there  are  common  features
oted  in  these  patients  and  with  adequate  insulin  treat-
ent  there  is  reversal  of  growth  failure  and  hepatomegaly
f  present.3
MS  is  more  common  in  children  and  adolescents  with
oor  glycemic  control  and  increased  susceptibility  of
omplications,1 and  is  the  commonest  cause  of  hepatic  dys-
unction  in  children  and  adolescents  with  DM1.4
Although  its  real  incidence  is  not  well-known,  due  to  the
educed  number  of  reported  cases  in  the  literature,  equal
ncidence  is  reported  in  males  and  females,  with  most  of  the
ases  occurring  in  adolescents  and  young  adults.2,5
The  authors  present  a  retrospective  analysis  of  patients
resenting  diagnostic  criteria  of  MS  from  the  type  1  diabetic
opulation  followed  currently  by  pediatric  endocrinology  in
raga’s  Hospital.
aterials and methods
ases  were  identiﬁed  by  searching  the  Pediatric  endocrinol-
gy  DM1  database  for  conﬁrmed  clinical  and  biochemical
eatures  of  MS  in  patients  under  18  years  at  presentation.  A
etrospective  analysis  was  undertaken.  A  review  of  records
as  conducted  to  determine  patients’  age  at  presentation  of
M1  and  MS,  as  well  as  glycated  hemoglobin  (HbA1c)  value,
epatic  enzymes,  lipid  proﬁle  and  median  daily  insulin  dose
t  MS  presentation  and  follow-up  data  after  MS  diagnosis.
ata  regarding  other  complications  of  DM1  (microvascularPlease  cite  this  article  in  press  as:  Dias  J,  et  al.  M
http://dx.doi.org/10.1016/j.endonu.2012.12.005
omplications,  speciﬁcally,  retinopathy  and  nephropathy;
acrovascular  complications  and  neuropathies)  were  also
ollected.  Data  research  ended  in  October  30,  2011.  The
tudy  was  approved  by  the  Braga’s  Hospital  pediatric
t
a
sndocrinology  coordinator  and  an  informed  consent  was
igned  by  parents  or  children  legal  guardians.
esults
rom  a  population  of  91  pediatric  patients  with  DM1  (fol-
owed  from  January  2005  to  October  2011),  we  identiﬁed  6
atients  with  diagnostic  criteria  for  MS:  5  girls  and  1  boy.
Regarding  the  six  patients  with  MS,  the  median  age  at  DM1
iagnosis  was  7.8  years  (3--11  years)  and  at  MS  presentation
5.3  years  (13--17  years).  The  median  interval  between  DM1
nd  MS  diagnosis  was  7.5  years  (range  4--14  years).  All  the
atients  were  under  intensive  insulin  therapy  with  a  median
aily  insulin  dose  of  0.88  U/kg.
All  had  a  previous  history  of  poor  glycemic  control
rior  to  the  MS  diagnosis  with  a  median  (glycosylated
emoglobin)  HbA1c  concentration  at  diagnosis  of  12.3%
range  10.5--13.5%).  The  median  HbA1c  of  the  DM1  pop-
lation  was  8.1%  (normal  HbA1c  <  6.5%).  Non-compliance
egarding  nutritional  and  insulin  therapy  and  self-monitoring
as  a  common  feature  of  all  identiﬁed  MS  cases.
At  presentation,  the  5  girls  presented  cushingoid
eatures,  puberty  dysfunction  (primary  amenorrhea  in
 patients  and  secondary  amenorrhea  in  3)  and  mixed
yslipidemia  (high  total  cholesterol,  low  HDL[high  density
ipoprotein]  cholesterol  and  high  triglycerides:  cut-off  val-
es  of  >200  mg/dl  for  total  cholesterol,  <  40  mg/dl  for  HDL
nd  >  180  mg/dl  for  triglycerides).  The  male  patient  pre-
ented  puberty  delay  and  dyslipidemia.
Of  the  6  patients,  5  presented  hepatomegaly  (4  conﬁrmed
y  abdominal  ultrasound),  and  all  showed  transaminase
levation:  aspartate  aminotransferase  (AST)  and  alanine
minotransferase  (ALT)  levels  3--22-fold  above  the  upper
ormal  limit.  Liver  function  tests  such  as  alkaline  phos-
hatase,  prothrombin/partial  prothrombin  time  and  total
ilirubin  were  normal,  as  well  as  thyroid  function,  IgA  and
ransglutaminase  or  anti-endomysium  levels.  None  of  the
atients  presented  criteria  of  short  stature  (all  were  withinauriac  syndrome  still  exists.  Endocrinol  Nutr.  2013.
he  percentiles  P10--P75  of  expected  height  for  age  and  sex,
ccording  to  CDC  2010  Growth  Charts).
Clinical  and  biochemical  features  at  MS  presentation  are
hown  in  Table  1.
Please  cite  this  article  in  press  as:  Dias  J,  et  al.  M
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After  diagnosis,  a  stronger  multidisciplinary  approach
involving  endocrinology,  pediatrics,  nutrition,  psychology
nd  psychiatry)  was  attempted  in  order  to  improve  glycemic
ontrol.  The  mean  duration  of  follow-up  was  1.8  years
1--3.5  years).
A  better  control  was  achieved  in  2  girls,  with  a reduction
f  HbA1c  to  concentrations  below  9%  and  an  improvement
egarding  puberty  impairment  (normalization  of  secondary
menorrhea).  Normalization  of  transaminase  concentrations
as  achieved  only  in  one.  A  third  patient  presented  transient
mproved  control  with  normalization  of  menses  and  transam-
nases.  In  another  patient,  a  normalization  of  transaminase
oncentrations  was  observed  with  a modest  decrease  of
bA1c  concentration  (from  14.5%  to  13%).  Normalization
f  transaminase  concentrations  occurred  between  4  and  12
eeks  (median  9  weeks)  after  MS  diagnosis.  In  the  sixth
atient  no  better  glycemic  control  was  achieved.  None  of
he  patients  showed  an  improvement  of  lipid  proﬁle.
The  6  patients  had  regular  ophthalmologic  evaluations
nd  none  showed  signs  of  diabetic  retinopathy.  Three  of  the
 presented  with  microalbuminuria  (>30  mg/dl  in  24  h).
iscussion
dolescence  is  a  critical  period  of  development  charac-
erized  by  changes  in  interpersonal  roles,  responsibilities
nd  identity  construction.  This  period  is  more  complex  for
dolescents  diagnosed  with  type  1  diabetes:  in  addition
o  experiencing  the  same  challenges  as  their  peers,  these
dolescents  must  deal  with  intensive  medical  regimens,
egular  clinic  appointments,  carbohydrate  calculations  and
requent  daily  monitoring  of  blood  glucose  levels.  Although
ew  insulins  and  carbohydrate  counting  approach  are  cur-
ently  available  to  facilitate  more  optimal  glycemic  control,
any  adolescents  with  type  1  diabetes  achieve  suboptimal
lycemic  control  and  in  some  cases  we  can  still  ﬁnd  MS.
The  features  of  MS  are  mostly  related  with  deﬁcient
nsulinization.  Patients  can  develop  hepatomegaly  due  to
ntrahepatic  glycogen  deposition;  if  these  patients  also  have
levated  liver  enzymes,  dyslipidemia,  cushingoid  features
nd  delayed  growth  or  sexual  maturation,  Mauriac  syndrome
an  be  diagnosed.4 The  literature  documents  decreased
lood  glucose  monitoring  frequency  and  deterioration  in
lood  glucose  control  and  HbA1c,  with  few  adolescents
chieving  optimal  HbA1c  values  (<7.5%).6 Although  being  an
dolescent  greater  risk,  MS  can  occur  in  any  age  if  good
etabolic  control  is  not  achieved.2
In  poorly  controlled  DM1  patients,  the  hyperglycemic
eriods  followed  by  occasional  hyperinsulinization  and  the
igh  cortisol  levels  as  hypoglycemia  contra-regulatory  hor-
one  lead  to  hepatic  glycogen  storage.  In  hyperglycemic
ituations,  glucose  goes  freely  into  the  hepatocyte  and  is
lso  stored  as  glycogen.  On  the  other  hand,  the  deﬁcient
nsulinization  due  to  poor  glycemic  control  leads  to  lipoly-
is  and  ketone  liberation.  Ketosis  activates  cortisol  synthesis
romoting  the  release  of  fatty  acids  and  hyperglycemia.7,8 A
ommon  ﬁnding  in  these  patients  is  the  growth  delay  and/orauriac  syndrome  still  exists.  Endocrinol  Nutr.  2013.
ypogonadism  secondary  to  the  high  cortisol  levels.4
The  fact  of  the  short  stature  classically  described  in  MS
ot  being  reported  here  might  have  two  explanations:  the
rst  is  that  all  the  patients  were  13--17  years  old  by  the
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ime  of  diagnosis,  meaning  that  they  had  already  achieved  a
ormal  stature  before  the  detioration  of  metabolic  control.
he  other  reason  is  that  data  of  parents’  height  was  not
vailable  in  order  to  evaluate  the  expected  genetic  height,
o  that  some  might  be  in  a  normal  percentile  for  sex  and  age
ut  below  their  genetic  potential.
As  in  other  series  of  cases  recently  described,  also  with
 small  number  of  patients,  the  incidence  of  MS  seems  to
e  greater  in  adolescent  girls.  The  poor  glycemic  control
rior  to  the  diagnosis  and  the  elevated  daily  insulin  dose
re  also  described  in  other  series.4,9 These  data  suggest  the
mportance  of  high  vigilance  in  promoting  patient  compli-
nce  to  insulin  dosing  rather  than  simply  increasing  insulin
osage  in  response  to  hyperglycemia  with  subsequent  weight
ain.
With  adequate  insulin  treatment  there  is  a  reversal  of
hose  features;  however,  overly  aggressive  insulin  delivery
ould  result  in  rapid  deterioration  of  diabetic  retinopathy
nd  nephropathy.3 The  reduction  of  hepatic  enzymes  after
chieving  reasonable  glycemic  control  suggests  that  liver
iopsy  and  other  extensive  work-up  may  be  unnecessary  in
he  management  of  similar  patients.9
The  authors  present  this  series  to  stress  the  importance
f  high  index  of  suspicion  of  MS  in  diabetic  adolescents
ith  hepatomegaly,  transaminase  elevation,  dyslipidemia,
rowth  or  sexual  delay  and  cushingoid  features.  A  prompt
iagnosis  and  a  multidisciplinary  approach  are  the  basis  of
he  treatment,  but  prevention  is  desirable.  Good  metabolic
ontrol  allows  improving  liver  function  tests  as  well  as
 reduction  of  the  probability  of  developing  other  dia-Please  cite  this  article  in  press  as:  Dias  J,  et  al.  M
http://dx.doi.org/10.1016/j.endonu.2012.12.005
etic  complications  related  to  persistent  hyperglycemia.
s  this  series  shows,  adolescents  and  especially  females
re  more  vulnerable  to  this  disease  and,  due  to  their
io-psycho-social  proﬁle,  therapeutic  adhesion  is  not  easy
9 PRESS
J.  Dias  et  al.
o  achieve,  despite  new  insulin  treatments  and  dietary
pproach.
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